BOLT — Bolt Biotherapeutics Income Statement
0.000.00%
Last trade - 00:00
- $23.29m
- -$50.41m
- $7.88m
- 23
- 52
- 40
- 32
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0.215 | 0.231 | 1.26 | 5.73 | 7.88 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Total Operating Expenses | 31.2 | 49.4 | 94 | 96 | 84.1 |
Operating Profit | -31 | -49.2 | -92.8 | -90.3 | -76.2 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -30.5 | -60.7 | -98.6 | -88.1 | -69.2 |
Net Income After Taxes | -30.5 | -60.7 | -98.6 | -88.1 | -69.2 |
Net Income Before Extraordinary Items | |||||
Net Income | -30.5 | -60.7 | -98.6 | -88.1 | -69.2 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -30.5 | -60.7 | -98.6 | -88.1 | -69.2 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.883 | -1.67 | -2.64 | -2.36 | -1.83 |
Dividends per Share |